Merozyne Therapeutics has been established to develop a treatment for MDC1A, a severe form of muscular dystrophy.
Merozyne Therapeutics has been established to develop a treatment for MDC1A, a severe form of muscular dystrophy.
DNA-directed RNA Interference (ddRNAi) is Benitec’s RNAi platform for gene silencing, with several advantages over other methods of gene silencing such as siRNA, anti-sense and zinc finger nucleases.